Global Fluid Biopsy Market Size, Share, Growth, Trends, and Forecast (2024 - 2031)
Global Fluid Biopsy Market Scope: Historical Data (2021 – 2022), Base Year (2023), Forecast Period (2024 – 2031)
Market Segmentation: By Product & Service (Assay Kits, Instruments, and Services), Circulating Biomarkers (Circulating Tumor Cells (CTCs), Circulating Nucleic Acids, Exosomes/ Microvesicles, and Circulating Proteins), Technology (Multi-gene-parallel Analysis (NGS), and Single Gene Analysis (PCR Microarrays)), End Use (Hospitals and Laboratories, Specialty Clinics, Academic and Research Centers, and Others), and Region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa)
Market Overview
The Global Fluid Biopsy Market was valued at USD 5,450.0 million in 2023 and is expected to reach USD 21,478.4 million by 2031 while growing at a CAGR of 18.7% during the forecast period (2024-2031).
*Note: Graph is shown for illustrative purposes only; complete datasets will be provided in the full report
Market Dynamics
This section of the report will analyze various driving and restraining factors that are expected to have a significant impact on the global fluid biopsy market growth. A fluid biopsy is a blood test designed to detect indications of cancerous tumors, such as tumor cells and cancer cell DNA. It serves as a simple and non-invasive alternative to surgical biopsies, allowing doctors to gather a spectrum of information about a tumor through a straightforward blood sample.
Fluid biopsies facilitate early detection of cancerous tumors by identifying circulating tumor cells (CTCs) and cancer cell-free DNA (cfDNA) in the bloodstream, allowing for timely intervention and treatment. The market is further propelled by the principles of Precision Medicine and Personalized Treatment. However, challenges such as limited clinical validation and technological complexity and standardization impede the market's growth.
Furthermore, the global fluid biopsy industry will be analyzed through various tools including PESTLE analysis, and Porter’s analysis.
Segmentation – By Product & Service Analysis
The Global Fluid Biopsy Market is segmented among Assay Kits, Instruments, and Services, based on Product & Service. In 2023, Assay Kits accounted for the majority of the market share*.
*Note: Graph is shown for illustrative purposes only; complete datasets will be provided in the full report
Segmentation – By Circulating Biomarkers Analysis
The Global Fluid Biopsy Market is segmented among Circulating Tumor Cells (CTCs), Circulating Nucleic Acids, Exosomes/ Microvesicles, and Circulating Proteins, based on Circulating Biomarkers. In 2023, Circulating Nucleic Acids accounted for the majority of the market share*.
*Note: Graph is shown for illustrative purposes only; complete datasets will be provided in the full report
Global Fluid Biopsy Market: Regional Analysis
Based on region, the market is divided into six regions including North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. In 2023, North America dominated the market with the highest market share, while Asia Pacific is expected to grow with the highest CAGR during the forecast period (2024 – 2031).
*Note: Graph is shown for illustrative purposes only; complete datasets will be provided in the full report
Competitive Landscape
Some of the key players operating in the market are Bio-Rad Laboratories, Diagnologix LLC, Exosome Sciences Inc., Grail Inc., Guardant Health, Horizon Discovery, Inivata Ltd, Illumina Inc., LungLife AI Inc., and Qiagen NV.
Table of Contents:
1. Research Methodology and Market Scope
Research Methodology
Market Scope
2. Executive Summary
3. Global Fluid Biopsy Market Dynamics
Drivers
Restraints
Opportunity
4. Global Fluid Biopsy Industry Analysis
PEST Analysis
Porter's Five Force Analysis
Recent Deals Analysis
5. Global Fluid Biopsy Market Segmentation, By Product & Service
Global Fluid Biopsy Market Share Analysis, By Product & Service
Global Fluid Biopsy Market Growth Analysis, By Product & Service
Global Fluid Biopsy Market Trends, By Product & Service
o Assay Kits
o Instruments
o Services
6. Global Fluid Biopsy Market Segmentation, By Circulating Biomarkers
Global Fluid Biopsy Market Share Analysis, By Circulating Biomarkers
Global Fluid Biopsy Market Growth Analysis, By Circulating Biomarkers
Global Fluid Biopsy Market Trends, By Circulating Biomarkers
o Circulating Tumor Cells (CTCs)
o Circulating Nucleic Acids
o Exosomes/ Microvesicles
o Circulating Proteins
7. Global Fluid Biopsy Market Segmentation, By Technology
Global Fluid Biopsy Market Share Analysis, By Technology
Global Fluid Biopsy Market Growth Analysis, By Technology
Global Fluid Biopsy Market Trends, By Technology
o Multi-gene-parallel Analysis (NGS)
o Single Gene Analysis (PCR Microarrays)
8. Global Fluid Biopsy Market Segmentation, By End Use
Global Fluid Biopsy Market Share Analysis, By End Use
Global Fluid Biopsy Market Growth Analysis, By End Use
Global Fluid Biopsy Market Trends, By End Use
o Hospitals and Laboratories
o Specialty Clinics
o Academic and Research Centers
o Others
9. Global Fluid Biopsy Market Segmentation, By Region
Global Fluid Biopsy Market Share Analysis, By Region
Global Fluid Biopsy Market Growth Analysis, By Region
Global Fluid Biopsy Market Trends, By Region
o North America
o Europe
o Asia Pacific
o Latin America
o Middle East
o Africa
10. Competitive Landscape
Bio-Rad Laboratories*
o Company Overview
o Financial Performance
o Key Development/Strategies
o SWOT Analysis
Diagnologix LLC
Exosome Sciences Inc.
Grail Inc.
Guardant Health
Horizon Discovery
Inivata Ltd
Illumina Inc.
LungLife AI Inc.
Qiagen NV
*Similar analysis will be provided for each company listed above.
